

DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl.* 2013;3(1):5–6.
2. Moe SM. Disorders of Phosphorous Homeostasis in CKD. *Calcium Phosphate Metab Manag Chronic Ren Dis.* 2007;13–28.
3. Yasin A, Liu D, Chau L, et al. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study. *BMC Nephrology.* 2013 ; 14 (39) : 1-8
4. Fourtounas C. Phosphorus metabolism in chronic kidney disease. *Hippokratia.* 2011;15 :50–2.
5. Vervloet M. Renal and Extrarenal Effects Of Fibroblast Growth Factor 23. *Nature Reviews Nephrology.* 2019;15:109-20.
6. Wesseling PK, Jüppner H. The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications. *Bone.* 2013;54(2): 222–9.
7. Hruska KA, Seifert M, Sugatani T. Pathophysiology of the Chronic Kidney Disease - Mineral Bone Disorder. *Curr Opin Nephrol Hypertens.* 2015;24(4):303-9.
8. Sprague SM, Martin KJ, Coyne DW. Phosphate Balance and CKD–Mineral Bone Disease. *Kidney Int Rep.* 2021;6(8):2049-58.
9. Cozzolino M, Dusso AS, Slatopolsky E. Role of Calcium-Phosphate Product

- and Bone Associated Proteins on Vascular Calcification in Renal Failure. *J Am Soc Nephrol.* 2001; 12: 2511-16.
10. Neill WC. The Fallacy of The Calcium-Phosphorus Product. *International Society of Nephrol.* 2007;72:792-6.
 11. Jung DH, Park B, Lee YJ. Longitudinal Effects of Serum Calcium and Phosphate Levels and Their Ratio on Incident Ischemic Heart Disease among Korean Adults. *Biomolecules.* 2022;12(103):2-11.
 12. Lederer E. Regulation of serum phosphate. *J Physiol.* 2014;592(18):3985-95.
 13. Pereira DC, Ataíde Lima RP, Teixeira de LR, et al. Association between obesity and calcium: phosphorus ratio in the habitual diets of adults in a city of northeastern brazil: an epidemiological study. *Nutrition Journal.* 2013;12(90):1-11.
 14. Vaart AV, Yeung S, Dijk PR, et al. Phosphate and fibroblast growth factor 23 in diabetes. *Clinical Science.* 2021;135:1669–87.
 15. Block GA, Shearon TE, Levin NW, et al. Association of Serum Phosphorus and Calcium X Phosphate Product With Mortality Risk in Chronic Hemodialysis Patients: A National Study. *American Journal of Kidney Diseases.* 1998;31(4):607-17.
 16. Menon V, Greene T, Pereira AA, et al. Relationship of Phosphorus and Calcium-Phosphorus Product With Mortality in CKD. *American Journal of Kidney Diseases.* 2005;46(3):455-63.
 17. Slawuta P, Kumiega E, Kopylowics AS, et al. An Attempt to use The Serum Concentration of the Phosphate (P_1) and the Ca x P Product As Markers of the

- Progression of Chronic Kidney Disease. *Polish Journal of Veterinary Sciences*. 2019;22(4):647–52.
18. Rocco MV, Berns JS. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis*. 2012;60(5):850–86.
 19. Russo D, Battaglia Y. Clinical Significance of FGF-23 in Patients with CKD. *Int J Nephrol*. 2011;1–5.
 20. Crews DC, Bello AK, Saadi G. Burden. Access and Disparities in Kidney Disease. *Kidney Dis*. 2019;5(2):126–33.
 21. Suwitra K. Penyakit Ginjal Kronik. In: Setiati S, Alwi, Sudoyo, editors. *Buku Ajar Ilmu Penyakit Dalam*. VI. Jakarta: Interna Publishing; 2015. p. 2163.
 22. Daugirdas J, Blake P. Handbook of dialysis. In: Raimann JG, editor. *Handbook of dialysis*. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 30.
 23. Indonesian Renal Registry. 11th Report Of Indonesian Renal Registry. 2018;1–46.
 24. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. *Kidney International*. 2012 ; 82 : 737–47.
 25. Vervloet MG, Sezer S, Massy ZA, et al. The Role of Phosphate in Kidney Disease. *Nature Nephrol*. 2017;13:27-38.
 26. Kumar R, Vallon V. Reduced Renal Calcium Excretion in the Absence of Sclerostin Expression: Evidence for a Novel Calcium-Regulating Bone Kidney Axis. *J Am Soc Nephrol*. 2014; 25: 2159–68.
 27. Moe SM. Rationale to reduce calcium intake in patients with CKD. *Curr Opin Nephrol Hypertens*. 2018 ; 27(4): 251–7.

28. Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. *Nephron - Clin Pract.* 2014;128(1–2):1–10.
29. Blaine J, Chonchol M, Levi M. Renal Control of Calcium, Phosphate, and Magnesium Homeostasis. *Clin J Am Soc Nephrol.* 2015;10: 1257–72.
30. Hanks LJ, Casazza K, Judd SE, et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. *PLoS One.* 2015;10(3):1–12.
31. Gallant KMH, Spiegel DM. Calcium Balance in Chronic Kidney Disease. *Curr Osteoporos Rep Springer.* 2017; 15: 214–21.
32. Wojcicki JM. Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: Results from the National Health and Nutrition Examination Survey (NHANES): 2005-2010. *BMC Nephrol.* 2013;14(1).
33. Tippen S.P, Noonan ML, Ni Pu, et al. Age and sex effects on FGF23-mediated response to mild phosphate challenge. *Elsevier.* 2021; 146:1-8.
34. Bellasi A, Mandreoli M, Baldrati L, et al. Chronic kidney disease progression and outcome according to serum phosphorus in mild-to- 37 moderate kidney dysfunction. *Clin J Am Soc Nephrol.* 2011;6(4):883-91.
35. Hanudel MR, Laster M, Salusky IB. Non-renal-Related Mechanisms of FGF23 Pathophysiology. *Curr Osteoporos Rep.* 2018;16(6):724–9.
36. Lanske B, Razzaque MS. Mineral metabolism and aging: the FGF-23 enigma Beate. *Curr Opin Nephrol Hypertens.* 2006;16(4):311–8.
37. Hanks LJ, Casazza K, Judd SE, et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in

- adults. PLoS One. 2015;10(3):1–12.
38. Kuczera P, Adamczak M, Wiecek A. Fibroblast growth factor-23—A potential uremic toxin. *Toxins (Basel)*. 2016;8(12):1–11.
 39. Ortiz MER, Lopez I, Castaneda JRM, et al. Calcium Deficiency Reduces Circulating Levels of FGF23. *J Am Soc Nephrol*. 2012; 23 : 1190-7.
 40. Quinn SJ, Thomsen ARB, Pang JL et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. *Am J Physiol Endocrinol Metab*. 2013; 304: 310-20.
 41. Deger SM, Mutluay R, Derici U, et al. Can Calcium, Phosphate, Calcium Phosphate Product and Intact Parathyroid Hormone Levels be Appropriately Controlled in Dialysis Patients?. *Med Princ Pract*. 2011; 20: 85-9.
 42. Hoar S, Morton AR, Meers C, et al. A Multidisciplinary Approach to The Control of Calcium x Phosphate Product in. *Dial Transplant*. 1999;28:309-13.
 43. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in Patients with End-Stage Renal Disease on Hemodialysis. *Kidney International*, 2004; 65 : 1943–6.
 44. Mahdavi S, Bellasi A, Nagra K, et al. Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients. *J Clin Med*. 2019; 8 (1680): 1-10.
 45. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast Growth Factor-23 Relationship to Dietary Phosphate and Renal Phosphate Handling in Healthy Young Men. *J Clin Endocrinol Metab*. 2005;90(3):1519–24.
 46. Saito H, Maeda A, Ohtomo S. Circulating FGF-23 Is Regulated by 1,25-Dihydroxyvitamin D₃ and Phosphorus in Vivo. *The Journal of Biological*

Chemistry.2005;280(4): 2543–9.

47. Mitchell DM, Uppner HJ, Bowie SM. FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. *J Clin Endocrinol Metab.* 2017; 102(4):1151–60.
48. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol.* 2005;16(2):520-8.
49. Montford JR, Chonchol M, Cheung AK, et al. Low Body Mass Index and Dyslipidemia in Dialysis Patients Linked to Elevated Plasma Fibroblast Growth Factor 23. *Am J Nephrol.* 2013;37:183–90.
50. Akter S, Eguchi M, Kochi T, et al. Association of Serum Calcium and Phosphate Concentrations with Glucose Metabolism Markers: The Furukawa Nutrition and Health Study. *Nutrients.* 2020;12(2344):1-13.
51. Muras K, Zagajewska AM, Nowicki M. Diabetes Modifies Effect of High-Phosphate Diet on Fibroblast Growth Factor-23 in Chronic Kidney Disease. *J Clin Endocrinol Metab.* 2013;98(12):1901–8.
52. Kritmetapak K, Losbanos L, Berent TE, et al. Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)₂D and normal FGF7 concentrations characterize patients with CKD. *BMC Nephrol.* 2021;22(1):21-8.
53. Isakova T, Wahl P, Vargas G, et al. FGF23, PTH and Phosphorus Metabolism in the Chronic Renal Insufficiency Cohort. *Kidney Int.* 2011; 79(12): 1370–8.

54. Haad CR, Ortiz ME, Malo AM. Phosphate control in reducing FGF23 levels in hemodialysis patients: Reduction of FGF23 in HD patients. Plos One. 2018; 1-23.
55. Waheed A.A, Pedraza F, Lenz O, et al. Phosphate control in end-stage renal disease: barriers and opportunities. Nephrol Dial Transplant. 2013; 28: 2961-8.